Dr. Ronald Kalff
Achtergrond - 17 april 2009
Dr Kalff is co-founder and CEO of Immpact, a biotech start-up company that is active in the field of immunology. Furthermore, he is advisor to the biotech investment fund BTF and to strategy consultants Roland Berger.
Donald Kalff earned a PhD from the Wharton School of the University of Pennsylvania, Philadelphia (US). In 1980 he joined Royal Dutch/Shell. At Shell he carried out assignments in marketing, oil and products trading, and in corporate and strategic planning, both in the Netherlands and the UK.
Ten years later Dr Kalff joined KLM Royal Dutch Airlines to become a member of the Executive Board, responsible for air political affairs, institutional relations, business planning, fleet planning and acquisition, and strategic alliances. From 1997 until 2000 he was KLM’s chief negotiator for mergers and long-term agreements.
For more information